Upgrade to SI Premium - Free Trial

Corvus Pharma (CRVS)

11.12 -0.60 (5.12%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/11/26)

Latest Headlines

Form 4 Corvus Pharmaceuticals, For: May 18 Filed by: MILLER RICHARD A MD May 20, 2026 4:12 PM - SEC Filing Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference May 20, 2026 4:01 PM - Globe NewsWire Form SCHEDULE 13G/A Corvus Pharmaceuticals, Filed by: Point72 Asset Management, L.P. May 15, 2026 4:20 PM - SEC Filing Form SCHEDULE 13G Corvus Pharmaceuticals, Filed by: Sirenia Capital Management LP May 15, 2026 8:11 AM - SEC Filing Corvus Pharmaceuticals (CRVS) Reiterated at Overweight by Cantor Fitzgerald May 15, 2026 7:33 AM - StreetInsider Form 8-K Corvus Pharmaceuticals, For: May 14 May 14, 2026 7:01 AM - SEC Filing Corvus Pharmaceuticals presents soquelitinib atopic dermatitis data May 14, 2026 7:00 AM - StreetInsider Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting May 14, 2026 7:00 AM - Globe NewsWire Form S-8 Corvus Pharmaceuticals, May 7, 2026 5:03 PM - SEC Filing Corvus Pharmaceuticals, Inc. (CRVS) Reports In-Line Q1 EPS May 7, 2026 4:24 PM - StreetInsider Form 10-Q Corvus Pharmaceuticals, For: Mar 31 May 7, 2026 4:06 PM - SEC Filing Form 8-K Corvus Pharmaceuticals, For: May 07 May 7, 2026 4:02 PM - SEC Filing Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results May 7, 2026 4:01 PM - Globe NewsWire Form 3 Corvus Pharmaceuticals, For: Apr 23 Filed by: Chan Andrew C. April 27, 2026 5:33 PM - SEC Filing Form 4 Corvus Pharmaceuticals, For: Apr 23 Filed by: Chan Andrew C. April 27, 2026 5:33 PM - SEC Filing Form SCHEDULE 13G/A Corvus Pharmaceuticals, Filed by: BlackRock, Inc. April 27, 2026 4:15 PM - SEC Filing Form DEFA14A Corvus Pharmaceuticals, April 24, 2026 4:18 PM - SEC Filing Form DEF 14A Corvus Pharmaceuticals, For: Jun 11 April 24, 2026 4:16 PM - SEC Filing Form 8-K Corvus Pharmaceuticals, For: Apr 22 April 23, 2026 7:02 PM - SEC Filing Corvus Pharmaceuticals adds former Genentech executive to board April 23, 2026 7:30 AM - StreetInsider Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors April 23, 2026 7:30 AM - Globe NewsWire Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting April 21, 2026 7:30 AM - Globe NewsWire Goldman Sachs sees nearly 140% upside in this biopharma stock April 20, 2026 7:30 AM - StreetInsider Goldman Sachs Starts Corvus Pharmaceuticals (CRVS) at Buy April 17, 2026 4:34 AM - StreetInsider Bernstein on US Pharma and Biotech: Who might buy whom? April 13, 2026 5:52 AM - StreetInsider Form SCHEDULE 13G/A Corvus Pharmaceuticals, Filed by: VANGUARD GROUP INC March 26, 2026 5:39 PM - SEC Filing Corvus Pharma (CRVS) files mixed shelf March 13, 2026 8:51 AM - StreetInsider Form 8-K Corvus Pharmaceuticals, For: Mar 13 March 13, 2026 8:47 AM - SEC Filing Form 424B5 Corvus Pharmaceuticals, March 13, 2026 8:42 AM - SEC Filing Form S-3ASR Corvus Pharmaceuticals, March 13, 2026 8:02 AM - SEC Filing Corvus Pharmaceuticals (CRVS) Reiterated at Overweight by Cantor Fitzgerald March 13, 2026 7:23 AM - StreetInsider Corvus Pharmaceuticals (CRVS) PT Raised to $33 at Oppenheimer March 13, 2026 6:25 AM - StreetInsider Form 10-K Corvus Pharmaceuticals, For: Dec 31 March 12, 2026 4:06 PM - SEC Filing Form 8-K Corvus Pharmaceuticals, For: Mar 12 March 12, 2026 4:03 PM - SEC Filing Corvus Pharmaceuticals, Inc. (CRVS) Misses Q4 EPS by 2c March 12, 2026 4:02 PM - StreetInsider Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results March 12, 2026 4:01 PM - Globe NewsWire Full Article List